Merck Serono will use the facility for clinical bioanalysis and biomarker characterisation to find gene mutations among the Chinese population and ultimately develop personalised medicines. Being at the Pharmaron campus will give Merck Serono contract research organisation (CRO) support.
“Through this unique partnership, we are providing Merck Serono with a favourable environment as well as qualified staff to lead their drug development programs for local and regional clinical trials against local diseases and unmet medical needs”, Boliang Lou, chair and CEO of Pharmaron, said.